|
 |
|
|||||||
|
|||||||||
Diabetes Care 30:1689-1693, 2007
DOI: 10.2337/dc06-2272
© 2007 by the American Diabetes Association
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical Care/Education/Nutrition |
Impact of Oral Antihyperglycemic Therapy on All-Cause Mortality Among Patients With Diabetes in the Veterans Health Administration
1 Center for Health Care Knowledge and Management, VA New Jersey Health Care System, East Orange, New Jersey
2 School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey
3 Deep South Center on Effectiveness, Birmingham VA Medical Center, Birmingham, Alabama
Address correspondence and reprint requests to Kristijan H. Kahler, PhD, RPh, Novartis Pharmaceuticals, One Health Plaza, Room 405/3117, East Hanover, NJ 07936. E-mail: kristijan.kahler{at}novartis.com
OBJECTIVE— The objective of this analysis was to evaluate the impact of several classes of oral antihyperglycemic therapy relative to sulfonylurea monotherapy on all-cause mortality among a cohort of patients with diabetes from the Veterans Health Administration (VHA).
RESEARCH DESIGN AND METHODS— A retrospective cohort study using data obtained from the VHA Diabetes Epidemiology Cohort was used. Users of oral antihyperglycemic therapy were classified into the following cohorts: sulfonylurea monotherapy, metformin monotherapy, metformin plus sulfonylurea, thiazolidinedione (TZD) use alone or in combination with other oral agents (TZD users), and no drug therapy. All-cause mortality was the outcome of interest. Multivariate mixed models incorporating a propensity score to account for imbalance among cohorts were used to estimate drug effects on mortality with associated 95% CIs.
RESULTS— A total of 39,721 patients with diabetes were included in the study. Adjusted odds ratios and 95% CIs for all-cause mortality were 0.87 (0.68–1.10) for metformin monotherapy users, 0.92 (0.82–1.05) for metformin plus sulfonylurea users, and 1.04 (0.75–1.46) for TZD users, relative to sulfonylurea monotherapy users.
CONCLUSIONS— We did not find any significant drug effect on all-cause mortality for any oral treatment cohorts relative to sulfonylurea oral monotherapy.
Abbreviations: DEpiC, Diabetes Epidemiology Cohort • LHSVE, Large Health Survey of Veteran Enrollees • TZD, thiazolidinedione • UKPDS, U.K. Prospective Diabetes Study • VHA, Veterans Health Administration
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  W. C. Winkelmayer, S. Setoguchi, R. Levin, and D. H. Solomon Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy Arch Intern Med, November 24, 2008; 168(21): 2368 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Approaches to Treatment of Type 2 Diabetes Diabetes Care, August 1, 2008; 31(8): 1697 - 1703. [Full Text] [PDF]
|
|
|
|
|
|
A. D. Rao, N. Kuhadiya, K. Reynolds, and V. A. Fonseca Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: A meta-analysis of observational studies Diabetes Care, August 1, 2008; 31(8): 1672 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Halanych, M. M. Safford, W. C. Keys, S. D. Person, J. M. Shikany, Y.-I. Kim, R. M. Centor, and J. J. Allison Burden of Comorbid Medical Conditions and Quality of Diabetes Care Diabetes Care, December 1, 2007; 30(12): 2999 - 3004. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |